Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

FHS
July 17, 2024
9:58 am

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug

What You Should Know: Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study

December 8, 2023

Merck’s KEYTRUDA regimen gets positive EMA CHMP opinion

Share this article Merck’s Keytruda received approval in the US in October 2023. Credit: Atmosphere1 / Shutterstock.com. Merck (MSD)’s anti-programmed death receptor-1 (PD-1) therapy Keytruda

February 26, 2024

Being Health Unveils $5.4M-Backed Modern Mental Health Practice in Lower Manhattan

What You Should Know: Being Health, a psychiatrist-founded modern mental health practice, launches today to bring the best of psychiatry, psychotherapy, novel treatments (such as

January 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.